GSK343, a novel EZH2 inhibitor, has been shown to regulate apoptosis and autophagy by modulating canonical and non-canonical NF-κB/IκBα pathways and may demonstrate efficacy in inhibiting GBM cell proliferation in vitro and tumor growth in subcutaneously transplanted tumor mouse models [179]. This evidence concerns the gene EZH2 and glioblastoma.